SI2473605T1 - Cepivo pcsk9 - Google Patents
Cepivo pcsk9 Download PDFInfo
- Publication number
- SI2473605T1 SI2473605T1 SI201031682T SI201031682T SI2473605T1 SI 2473605 T1 SI2473605 T1 SI 2473605T1 SI 201031682 T SI201031682 T SI 201031682T SI 201031682 T SI201031682 T SI 201031682T SI 2473605 T1 SI2473605 T1 SI 2473605T1
- Authority
- SI
- Slovenia
- Prior art keywords
- immunogen
- pcsk9
- group
- terminus
- immunogenic composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
Claims (28)
- CEPIVO PCSK9 Patentni zahtevki1. Imunogen, ki obsega vsaj en antigeni PCSK9-peptid, vezan na imunogeni nosilec, pri čemer je antigeni PCSK9-peptid izbran iz skupine, ki sestoji iz SEQ ID št. od 182 do 226 ali od 330 do 359 in pri čemer je imunogeni nosilec izbran izmed toksoida davice, CRM197 ali VLP, ki je izbran izmed HBcAg, HBsAg, Obeta, PP7, PPV ali Norvvalk Virus VLP.
- 2. Imunogen po zahtevku 1, pri čemer je imunogeni nosilec izbran izmed CRM197 ali Obeta VLP.
- 3. Imunogen po katerem koli od zahtevkov od 1 do 2, pri čemer je antigeni PCSK9-peptid izbran iz skupine, ki sestoji iz SEQ ID št. 184,186,187,188 in 332.
- 4. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer antigeni PCSK9-peptid dalje obsega bodisi: - na svojem C-koncu linker, ki ima formulo (G)nC, (G)nSC ali (G)nK, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0,1,2, 3,4, 5, 6, 7, 8, 9 in 10, - na svojem N-koncu linker, ki ima formulo C(G)n, CS(G)n ali K(G)n, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0,1,2, 3,4, 5, 6, 7, 8, 9 in 10, - na svojem C-koncu linker, ki ima formulo (G)nC, (G)nSC ali (G)nK, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 in 10, in na svojem N-koncu linker, ki ima formulo C(G)n, CS(G)n ali K(G)n, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0, 1,2, 3, 4, 5, 6, 7, 8, 9 in 10.
- 5. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer antigeni PCSK9-peptid dalje obsega bodisi: - na svojem C-koncu linker, ki ima formulo (G)nC, (G)nSC ali (G)nK, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0,1 ali 2, - na svojem N-koncu linker, ki ima formulo C(G)n, CS(G)n ali K(G)n, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0,1 ali 2, - na svojem C-koncu linker, ki ima formulo (G)nC, (G)nSC ali (G)nK, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0,1 ali 2, in na svojem N-koncu linker, ki ima formulo C(G)n, CS(G)n ali K(G)n, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0,1 ali 2.
- 6. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer antigeni PCSK9-peptid dalje obsega cistein na svojem C-koncu.
- 7. Imunogen po zahtevku 6, pri čemer antigeni PCSK9-peptid dalje obsega CG-skupino ali cistein na svojem N-koncu.
- 8. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer antigeni PCSK9-peptid dalje obsega CGG na svojem N-koncu.
- 9. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer antigeni PCSK9-peptid dalje obsega GGC na svojem C-koncu.
- 10. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer je antigeni PCSK9-peptid cikliziran in obsega fragment cistein, (G)nC ali C(G)n, pri čemer je n celo število, izbrano iz skupine, ki sestoji iz 0, 1,2, 3, 4, 5, 6, 7, 8, 9 in 10.
- 11. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer je antigeni PCSK9-peptid cikliziran in obsega fragment cistein, GC ali CG.
- 12. Imunogen po katerem koli od zahtevkov od 1 do 3, pri čemer antigeni PCSK9-peptid dalje obsega KG ali KGG na svojem N-koncu.
- 13. Imunogen po zahtevku 4, pri čemer antigeni PCSK9-peptid obsega linker, kije izbran iz skupine, ki sestoji iz SEQ ID št. 317, 401,402 in 403.
- 14. Imunogen po katerem koli od zahtevkov od 1 do 2, pri čemer je antigeni PCSK9-peptid konformacijsko omejen.
- 15. Imunogen po zahtevku 14, pri čemer je antigeni PCSK9-peptid izbran iz skupine, ki sestoji iz SEQ ID št. 317, 401,402 in 403.
- 16. Imunogen po katerem koli od zahtevkov od 1 do 15, pri čemer je imunogen sposoben, kadar se daje posamezniku, znižati raven LDL-holesterola v krvi posameznika za vsaj 2 %, 5 %, 10 %, 20 %, 30 % ali 50 %.
- 17. Sestavek, ki obsega vsaj dva imunogena po katerem koli od zahtevkov od 1 do 16.
- 18. Imunogeni sestavek, ki obsega imunogen po katerem koli od zahtevkov od 1 do 16 ali sestavek imunogenov po zahtevku 17, ki dalje obsega vsaj en adjuvans.
- 19. Imunogeni sestavek po zahtevku 18, pri čemer je adjuvans izbran izmed galuna, CpG ODN, QS21 in lscomatrixa.
- 20. Farmacevtski sestavek, ki obsega imunogen po katerem koli od zahtevkov od 1 do 16 ali sestavek imunogenov po zahtevku 17 ali imunogeni sestavek po katerem koli od zahtevkov od 18 do 19 in farmacevtsko sprejemljivo pomožno snov.
- 21. Imunogen po katerem koli od zahtevkov od 1 do 16 ali sestavek imunogenov po zahtevku 17 ali imunogeni sestavek po katerem koli od zahtevkov od 18 do 19 ali farmacevtski sestavek po zahtevku 20 za uporabo kot zdravilo.
- 22. Imunogen po katerem koli od zahtevkov od 1 do 16 ali sestavek imunogenov po zahtevku 17 ali imunogeni sestavek po katerem koli od zahtevkov od 18 do 19 ali farmacevtski sestavek po zahtevku 20 za uporabo pri postopku preprečevanja, lajšanja ali zdravljenja obolenja, povezanega s PCSK9.
- 23. Imunogen, imunogeni sestavek ali farmacevtski sestavek za uporabo po zahtevku 22, pri čemer je obolenje, ki je povezano s PCSK9, povišan LDL-holesterol ali stanje, povezano s povišanim LDL-holesterolom.
- 24. Imunogen, imunogeni sestavek ali farmacevtski sestavek za uporabo po zahtevku 22, pri čemer je obolenje, povezano s PCSK9, izbrano izmed lipidnega obolenja, kot so hiperlipidemija, hiperlipidemija tipa I, tipa II, tipa III, tipa IV ali tipa V, sekundarna hipertrigliceridemija, hiperholesterolemija, družinska hiperholesterolemija, ksantomatoza, pomanjkanje holesterol-acetiltransferaze; ateriosklerotičnih stanj (npr. ateroskeroze), bolezni koronarnih arterij in srčnožilne bolezni.
- 25. Imunogen po katerem koli od zahtevkov od 1 do 16 ali sestavek imunogenov po zahtevku 17 ali imunogeni sestavek po katerem koli od zahtevkov od 18 do 19 za uporabo pri preprečevanju, lajšanju ali zdravljenju Alzheimerjeve bolezni.
- 26. Nukleinska kislina, ki kodira Imunogen po katerem koli od zahtevkov od 1 do 16.
- 27. Ekspresijski vektor, ki obsega nukleinsko kislino po zahtevku 26.
- 28. Gostiteljska celica, ki obsega ekspresijski vektor po zahtevku 27.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23954109P | 2009-09-03 | 2009-09-03 | |
PCT/IB2010/053784 WO2011027257A2 (en) | 2009-09-03 | 2010-08-23 | Pcsk9 vaccine |
EP10754583.2A EP2473605B1 (en) | 2009-09-03 | 2010-08-23 | Pcsk9 vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2473605T1 true SI2473605T1 (sl) | 2018-06-29 |
Family
ID=43413463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201031682T SI2473605T1 (sl) | 2009-09-03 | 2010-08-23 | Cepivo pcsk9 |
Country Status (30)
Country | Link |
---|---|
US (4) | US8889144B2 (sl) |
EP (3) | EP2473605B1 (sl) |
JP (5) | JP2013503623A (sl) |
KR (3) | KR101660578B1 (sl) |
CN (3) | CN104587462B (sl) |
AR (2) | AR078247A1 (sl) |
AU (1) | AU2010290931B2 (sl) |
BR (1) | BR112012004807A2 (sl) |
CA (2) | CA2846746A1 (sl) |
CO (1) | CO6501190A2 (sl) |
DK (1) | DK2473605T3 (sl) |
ES (1) | ES2670576T3 (sl) |
HK (3) | HK1174056A1 (sl) |
HU (1) | HUE037416T2 (sl) |
IL (2) | IL218229A (sl) |
MX (1) | MX2012002639A (sl) |
MY (1) | MY163512A (sl) |
NO (1) | NO2473605T3 (sl) |
NZ (3) | NZ620441A (sl) |
PE (3) | PE20161560A1 (sl) |
PH (2) | PH12016500004A1 (sl) |
PL (1) | PL2473605T3 (sl) |
PT (1) | PT2473605T (sl) |
RU (2) | RU2538162C2 (sl) |
SA (3) | SA110310687B1 (sl) |
SG (3) | SG178447A1 (sl) |
SI (1) | SI2473605T1 (sl) |
TR (1) | TR201808222T4 (sl) |
TW (1) | TWI400085B (sl) |
WO (1) | WO2011027257A2 (sl) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101721904B1 (ko) | 2008-08-29 | 2017-04-11 | 오럴 헬스 오스트레일리아 피티와이 엘티디 | P.진지발리스 감염의 예방, 치료 및 진단 |
ES2481040T3 (es) | 2008-12-09 | 2014-07-29 | Coley Pharmaceutical Group, Inc. | Oligonucleótidos inmunoestimulantes |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
GB201005005D0 (en) * | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
EP2680883B1 (en) * | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
EP2532359A1 (en) | 2011-06-10 | 2012-12-12 | Affiris AG | CETP fragments |
SI2570135T1 (sl) | 2011-09-13 | 2016-05-31 | Affiris Ag | PCSK9 cepivo |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
EP2703483A1 (en) * | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
WO2014060385A1 (en) * | 2012-10-17 | 2014-04-24 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
WO2014074509A1 (en) * | 2012-11-07 | 2014-05-15 | Vacplanta Limted | Production of an immunogen using a plant virus |
US10117923B2 (en) | 2012-11-07 | 2018-11-06 | Vacplanta Limited | Production of an immunogen using a plant virus |
TWI641382B (zh) * | 2013-01-31 | 2018-11-21 | 韓美藥品股份有限公司 | 於包含因子vii之組成物中使病毒失活之方法 |
CN104043120B (zh) * | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
US10004791B2 (en) * | 2014-02-28 | 2018-06-26 | Affiris Ag | Peptide vaccines against PCSK9 |
CN104558199B (zh) * | 2014-09-05 | 2018-07-06 | 成都康弘生物科技有限公司 | 一种治疗高胆固醇血症的融合蛋白制备及其用途 |
ES2878475T3 (es) * | 2015-07-20 | 2021-11-18 | Zoetis Services Llc | Composiciones adyuvantes liposomales |
EP3365006A1 (en) | 2015-10-19 | 2018-08-29 | Cadila Healthcare Limited | New adjuvant and vaccine composition containing the same |
AU2016348610B2 (en) * | 2015-11-03 | 2023-08-31 | Ac Immune Sa | Method for vaccination against a self-antigen in a human patient |
WO2017164409A1 (ja) * | 2016-03-25 | 2017-09-28 | 国立大学法人大阪大学 | 疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン |
EP3474875A1 (en) * | 2016-06-24 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Compositions and methods for treating cardiovascular disease |
CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
WO2018189705A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
CN107488215A (zh) * | 2017-07-19 | 2017-12-19 | 邱志华 | 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗 |
MX2022000094A (es) * | 2019-07-04 | 2022-04-27 | Cadila Healthcare Ltd | Vacuna a base de angptl3 para el tratamiento de enfermedad hepática. |
AU2021214166A1 (en) * | 2020-01-28 | 2022-09-22 | United Biomedical, Inc. | Peptide immunogens targeting PCSK9 and formulations thereof for prevention and treatment of PCSK9-mediated disorders |
GB2592769B (en) | 2020-03-01 | 2022-05-04 | Valneva Austria Gmbh | CpG-Adjuvanted SARS-CoV-2 virus vaccine |
WO2022147373A1 (en) * | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
GB2055131B (en) | 1978-09-29 | 1982-12-15 | Energy Secretary Of State For | Electrical power transmission in fluid wells |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
AU548727B2 (en) | 1981-03-12 | 1986-01-02 | Gruppo Lepetit S.P.A. | Beta-lactam acetic acid derivatives |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
DE3280400D1 (de) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JPS60136512A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
JP2999579B2 (ja) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Dnaおよびその用途 |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
AU9052091A (en) | 1990-12-20 | 1992-07-22 | Smithkline Beecham Biologicals (Sa) | Vaccines based on hepatitis b surface antigen |
DE4202394A1 (de) | 1991-04-04 | 1992-10-08 | Teves Gmbh Alfred | Schwimmsattel-teilbelagscheibenbremse mit einem bremsengehaeuse aus leichtmetall |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
WO1993021769A1 (en) | 1992-05-06 | 1993-11-11 | President And Fellows Of Harvard College | Diphtheria toxin receptor-binding region |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
EP0817854A2 (en) | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
JP2001513776A (ja) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用 |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
ATE370740T1 (de) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
CA2291483C (en) | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
TR200002338T2 (tr) | 1998-02-12 | 2002-06-21 | Immune Complex Corporation | Stratejik olarak yenilenmiş hepatit B çekirdek proteinler. |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
ES2188003T3 (es) | 1998-09-18 | 2003-06-16 | Pentapharm Ag | Inhibidores de la uroquinasa. |
AU5728099A (en) | 1998-09-28 | 2000-05-01 | Hans Balle Aps | Lift, preferably for seats on wheelchairs |
US6203837B1 (en) | 1998-10-06 | 2001-03-20 | Xcafe' Llc | Coffee system |
PT1126876E (pt) | 1998-10-16 | 2007-04-30 | Glaxosmithkline Biolog Sa | Sistemas adjuvantes e vacinas |
WO2000023955A1 (en) | 1998-10-21 | 2000-04-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Virus-like particles for the induction of autoantibodies |
WO2000026385A1 (en) | 1998-11-05 | 2000-05-11 | Powderject Vaccines, Inc. | Nucleic acid constructs for genetic immunization |
BR9915771A (pt) | 1998-11-30 | 2001-12-26 | Cytos Biotechnology Ag | Apresentação molecular ordenada de antìgenos,processo de preparação e utilização |
PT1140157E (pt) | 1998-12-21 | 2009-05-06 | Medimmune Inc | Proteínas de streptococcus pneumoniae e fragmentos imunogénicos para vacinas |
NZ512574A (en) | 1998-12-23 | 2004-03-26 | Iaf Biochem Int | Novel streptococcus antigens useful as vaccines |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
NZ513935A (en) | 1999-02-17 | 2004-02-27 | Csl Ltd | Immunogenic complexes and methods relating thereto |
EP1880735A3 (en) | 1999-03-19 | 2008-03-12 | GlaxoSmithKline Biologicals S.A. | Vaccine |
US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
AU764969B2 (en) | 1999-04-19 | 2003-09-04 | Smithkline Beecham Biologicals (Sa) | Vaccines |
NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
CO5200838A1 (es) | 1999-09-24 | 2002-09-27 | Smithkline Beecham Corp | Vacunas |
IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
AU783118B2 (en) | 1999-09-27 | 2005-09-29 | Coley Pharmaceutical Gmbh | Methods related to immunostimulatory nucleic acid-induced interferon |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
BR0109919A (pt) | 2000-04-07 | 2003-03-11 | Univ Leeds Innovations Ltd | Proteìna, partìcula, molécula de ácido nucleico, célula hospedeira, processo para produzir uma proteìna, composição farmacêutica, uso de uma proteìna, e, método de vacinação profilática ou terapêutica de um indivìduo |
AU2001252458A1 (en) | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
IL153558A0 (en) | 2000-06-20 | 2003-07-06 | Shire Biochem Inc | Streptococcus antigens |
ES2260235T3 (es) | 2000-06-22 | 2006-11-01 | Ucb Pharma Limited | Modificacion del antigeno "core" de la hepatitis b. |
AU2001269272A1 (en) | 2000-07-15 | 2002-01-30 | Lighthouse Display International Limited | Shelf edge display fittings |
GB0121171D0 (en) * | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
WO2003024481A2 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US20030091593A1 (en) | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
EP1432443B1 (en) | 2001-10-05 | 2009-01-21 | Cytos Biotechnology AG | Angiotensin peptide-carrier conjugates and uses thereof |
US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
EP1517702A4 (en) | 2002-02-21 | 2006-05-03 | Apovia Inc | IMMUNOGENIC HBC CHIMERIC PARTICLES STABILIZED WITH AN N-TERMINAL END CYSTEINE |
GB0209878D0 (en) | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
CA2489410C (en) | 2002-07-17 | 2015-01-13 | Cytos Biotechnology Ag | Molecular antigen arrays |
GB0219524D0 (en) * | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
AU2003300841B2 (en) | 2002-12-10 | 2008-03-20 | Lorantis Ltd. | Stabilized immunogenic HBc chimer particles |
CA2518669C (en) | 2003-03-13 | 2014-07-29 | Glaxosmithkline Biologicals S.A. | Purification process |
EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
WO2006134423A2 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
EP1991678B2 (en) | 2006-02-15 | 2020-07-15 | Rechtsanwalt Thomas Beck | Compositions and methods for oligonucleotide formulations |
WO2007128121A1 (en) * | 2006-05-08 | 2007-11-15 | Adaerata, Limited Partnership | Chimeric pcsk9 proteins, cells comprising same, and assays using same |
US7572618B2 (en) * | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US20080166785A1 (en) | 2006-08-16 | 2008-07-10 | Monica Sala-Schaeffer | Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use |
US8263353B2 (en) * | 2007-03-27 | 2012-09-11 | Merck Sharp & Dohme Corp. | Method for detecting autoprocessed, secreted PCSK9 |
WO2008125623A2 (en) * | 2007-04-13 | 2008-10-23 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
CN101883583B (zh) | 2007-06-26 | 2017-05-17 | 葛兰素史密丝克莱恩生物有限公司 | 含有肺炎链球菌荚膜多糖缀合物的疫苗 |
JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
BRPI0818765A8 (pt) * | 2007-10-26 | 2016-02-10 | Schering Corp | Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo |
CN101951943A (zh) | 2007-12-20 | 2011-01-19 | 赛托斯生物技术公司 | 神经生长因子偶联物及其用途 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
TWI445716B (zh) * | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9拮抗劑類 |
AT507604A1 (de) | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | Behandlung von atherosklerose |
US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
US10114918B2 (en) | 2016-01-27 | 2018-10-30 | Arm Limited | Physical placement control for an integrated circuit based on state bounds file |
EP3928994A1 (en) | 2016-06-23 | 2021-12-29 | Ripples Ltd. | Printing on a drink in accordance with a container property |
-
2010
- 2010-08-23 MX MX2012002639A patent/MX2012002639A/es active IP Right Grant
- 2010-08-23 EP EP10754583.2A patent/EP2473605B1/en not_active Not-in-force
- 2010-08-23 EP EP18158216.4A patent/EP3358008A1/en not_active Withdrawn
- 2010-08-23 MY MYPI2012000934A patent/MY163512A/en unknown
- 2010-08-23 CN CN201510017534.XA patent/CN104587462B/zh not_active Expired - Fee Related
- 2010-08-23 NZ NZ620441A patent/NZ620441A/en not_active IP Right Cessation
- 2010-08-23 CA CA2846746A patent/CA2846746A1/en not_active Abandoned
- 2010-08-23 PT PT107545832T patent/PT2473605T/pt unknown
- 2010-08-23 NZ NZ710626A patent/NZ710626A/en not_active IP Right Cessation
- 2010-08-23 PE PE2016002242A patent/PE20161560A1/es not_active Application Discontinuation
- 2010-08-23 KR KR1020137034292A patent/KR101660578B1/ko active IP Right Grant
- 2010-08-23 DK DK10754583.2T patent/DK2473605T3/en active
- 2010-08-23 WO PCT/IB2010/053784 patent/WO2011027257A2/en active Application Filing
- 2010-08-23 NZ NZ599059A patent/NZ599059A/en not_active IP Right Cessation
- 2010-08-23 ES ES10754583.2T patent/ES2670576T3/es active Active
- 2010-08-23 BR BR112012004807A patent/BR112012004807A2/pt not_active Application Discontinuation
- 2010-08-23 CN CN201510017173.9A patent/CN104548089B/zh not_active Expired - Fee Related
- 2010-08-23 SG SG2012010740A patent/SG178447A1/en unknown
- 2010-08-23 PE PE2012000286A patent/PE20121544A1/es active IP Right Grant
- 2010-08-23 SI SI201031682T patent/SI2473605T1/sl unknown
- 2010-08-23 CN CN201080049440.6A patent/CN102612558B/zh not_active Expired - Fee Related
- 2010-08-23 TR TR2018/08222T patent/TR201808222T4/tr unknown
- 2010-08-23 CA CA2771770A patent/CA2771770A1/en not_active Abandoned
- 2010-08-23 KR KR1020137034291A patent/KR101660577B1/ko active IP Right Grant
- 2010-08-23 HU HUE10754583A patent/HUE037416T2/hu unknown
- 2010-08-23 NO NO10754583A patent/NO2473605T3/no unknown
- 2010-08-23 AU AU2010290931A patent/AU2010290931B2/en not_active Ceased
- 2010-08-23 JP JP2012527419A patent/JP2013503623A/ja not_active Withdrawn
- 2010-08-23 RU RU2012107657/10A patent/RU2538162C2/ru not_active IP Right Cessation
- 2010-08-23 EP EP20140198381 patent/EP2865752A1/en not_active Withdrawn
- 2010-08-23 PE PE2016002226A patent/PE20161551A1/es not_active Application Discontinuation
- 2010-08-23 SG SG10201401516XA patent/SG10201401516XA/en unknown
- 2010-08-23 KR KR1020127005678A patent/KR101512053B1/ko not_active IP Right Cessation
- 2010-08-23 PL PL10754583T patent/PL2473605T3/pl unknown
- 2010-08-23 SG SG10201401515YA patent/SG10201401515YA/en unknown
- 2010-08-27 TW TW099128951A patent/TWI400085B/zh not_active IP Right Cessation
- 2010-08-31 US US12/872,645 patent/US8889144B2/en not_active Expired - Fee Related
- 2010-09-01 AR ARP100103197A patent/AR078247A1/es not_active Application Discontinuation
- 2010-09-01 SA SA110310687A patent/SA110310687B1/ar unknown
- 2010-09-01 SA SA114350179A patent/SA114350179B1/ar unknown
- 2010-09-01 SA SA114350178A patent/SA114350178B1/ar unknown
-
2012
- 2012-02-20 IL IL218229A patent/IL218229A/en not_active IP Right Cessation
- 2012-02-24 CO CO12033031A patent/CO6501190A2/es unknown
-
2013
- 2013-01-23 HK HK13101001.0A patent/HK1174056A1/xx not_active IP Right Cessation
-
2014
- 2014-10-07 US US14/508,977 patent/US9481875B2/en not_active Expired - Fee Related
- 2014-10-29 RU RU2014143531A patent/RU2014143531A/ru not_active Application Discontinuation
-
2015
- 2015-02-04 JP JP2015020387A patent/JP5859150B2/ja not_active Expired - Fee Related
- 2015-09-11 HK HK15108893.4A patent/HK1208346A1/xx not_active IP Right Cessation
- 2015-10-21 HK HK15110331.0A patent/HK1209619A1/xx not_active IP Right Cessation
- 2015-12-15 JP JP2015244111A patent/JP2016106089A/ja not_active Withdrawn
-
2016
- 2016-01-04 PH PH12016500004A patent/PH12016500004A1/en unknown
- 2016-01-06 PH PH12016500040A patent/PH12016500040A1/en unknown
- 2016-09-15 US US15/266,812 patent/US9987341B2/en not_active Expired - Fee Related
- 2016-10-06 JP JP2016198088A patent/JP2017039748A/ja active Pending
- 2016-12-07 AR ARP160103766A patent/AR107020A2/es unknown
-
2017
- 2017-09-19 IL IL254600A patent/IL254600A0/en unknown
- 2017-10-06 JP JP2017195839A patent/JP2018039821A/ja active Pending
-
2018
- 2018-04-19 US US15/957,835 patent/US20180318407A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2473605T1 (sl) | Cepivo pcsk9 | |
Ilyinskii et al. | Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release | |
Petrovsky | Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity | |
Silva et al. | Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses | |
AU766635B2 (en) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant | |
AU765824B2 (en) | Vaccines | |
TWI461209B (zh) | 包含抗原tau肽之免疫原及其組合物 | |
TWI232753B (en) | Adjuvant compositions comprising QS-21,3D-MPL and CpG and vaccine compositions comprising the same | |
US5795582A (en) | Adjuvant properties of poly (amidoamine) dendrimers | |
TWI457133B (zh) | 新穎組合物 | |
WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
Azuar et al. | Poly (hydrophobic amino acid)-based self-adjuvanting nanoparticles for Group A Streptococcus vaccine delivery | |
DK2822947T3 (en) | ARGINAL SALTS OF A TLR-7 AGONIST | |
CA2963897C (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
JP2003526676A (ja) | ワクチン用のアジュバント | |
Chua et al. | Opinion: making inactivated and subunit-based vaccines work | |
RU2014140731A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
US9700615B2 (en) | Adjuvant formulations and methods | |
Osorio et al. | Immune responses to hepatitis B surface antigen following epidermal powder immunization | |
Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
Ohtake et al. | Recombinant therapeutic protein vaccines | |
JP2016532712A (ja) | 薬物中毒に対するワクチン組成物 | |
CN101675994B (zh) | 治疗性疫苗制剂 | |
WO1998046263A1 (en) | Saponin adjuvants in combination with dna vaccination | |
Morelli et al. | ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines |